Circulating Vitamin D binding protein, total, free and bioavailable 25-hydroxyVitamin D and risk of colorectal cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ying, Hou Qun ^a,b   Sun, Hui Ling ^b,c   He, Bang Shun ^b   Pan, Yu Qin ^b   Wang, Feng ^b   Deng, Qi Wen ^b   Chen, Jie ^b,c   Liu, Xian ^b   Wang, Shu Kui ^a,b  

^a SOUTHEAST UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c NANJING NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

25-HYDROXYVITAMIN D; VITAMIN D; VITAMIN D BINDING PROTEIN;

ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; COLORECTAL TUMOR; FEMALE; GENETIC ASSOCIATION STUDY; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; RISK FACTOR; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; RISK FACTORS; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84944747629     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07956     Document Type: Article

References (36)

1. Feshanich, D. et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 13, 1502-1508 (2004).
2. Ma, Y. et al. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol 29, 3775-3782 (2011).
3. Park, S. Y. et al. Calcium and vitamin D intake and risk of colorectal cancer: the Multiethnic Cohort Study. Am J Epidemiol 165, 784-793 (2007).
4. Holick, M. F., Chen, T. C. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87, 1080S-1086S (2008).
5. Wu, K. et al. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 99, 1120-112 (2007).
6. Deeb, K. K., Trump, D. L., Johnson, C. S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7, 684-700 (2007).
7. Cross, H. S., Peterlik, M., Reddy, G. S., Schuster, I. Vitamin D metabolism in human colon adenocarcinoma-derived Caco-2 cells: expression of 25-hydroxyvitamin D3-1alpha-hydroxylase activity and regulation of side-chain metabolism. J Steroid Biochem Mol Biol 62, 21-28 (1997).
8. Bareis, P., Bises, G., Bischof, M. G., Cross, H. S.,Peterlik, M. 25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun 285, 1012-1017 (2001).
9. Tangpricha, V. et al. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 357, 1673-1674 (2001).
10. Bikle, D. D. et al. Assessment of the free fraction of 25-hydroxyvitaminDin serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 63, 954-959 (1986).
11. Brown, A. J., Coyne, D. W. Bioavailable vitamin D in chronic kidney disease. Kidney Int 82, 5-7 (2012).
12. Chishimba, L., Thickett, D. R., Stockley, R. A.,Wood, A. M. The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax 65, 456-462 (2010).
13. Grivennikov, S. I., Greten, F. R., Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
14. Weinstein, S. J. et al. Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin D and pancreatic cancer risk: a nested case-control study. Cancer Res 72, 1190-1198 (2012).
15. Mondul, A. M.,Weinstein, S. J., Moy, K. A., Mannisto, S., Albanes, D. Vitamin D-binding protein, circulating vitamin D and risk of renal cell carcinoma. Int J Cancer 134, 2699-2706 (2014).
16. Mondul, A. M.,Weinstein, S. J., Virtamo, J., Albanes, D. Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. Br J Cancer 107, 1589-1594 (2012).
17. Weinstein, S. J. et al. Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer 132, 2940-2947 (2013).
18. Bhan, I. et al. Bioavailable vitamin D ismore tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int 82, 84-89 (2012).
19. Zhang, J., Kew, R. R. Identification of a region in the vitamin D-binding protein that mediates its C5a chemotactic cofactor function. J Biol Chem 279, 53282-53287 (2004).
20. Anic, G. M., Weinstein, S. J., Mondul, A. M., Männistö, S., Albanes, D. Serum vitamin D, vitamin D binding protein, and risk of colorectal cancer. Plos One 9, e102966 (2014).
21. Weinstein, S. J. et al. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J cancer, doi:10.1002/ijc.29157 (2014).
22. Diaz, G. D., Paraskeva, C., Thomas, M. G., Binderup, L., Hague, A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 60, 2304-2312 (2000).
23. Zhao, X., Feldman, D. Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Endocrinology 132, 1808-1814 (1993).
24. Nykjaer,A. et al.An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96, 507-515 (1999).
25. Nykjaer, A. et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad SciUS A98, 13895-13900 (2001).
26. Cross, H. S. et al. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 66, 287-292 (2001).
27. Peng, X. et al. Regulation of CYP24 splicing by 1,25-dihydroxyvitamin D(3) in human colon cancer cells. J Endocrinol 212, 207-215 (2012).
28. Rehder, D. S., Nelson, R. W., Borges, C. R. Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci 18, 2036-2042 (2009).
29. Yamamoto, N., Suyama, H., Nakazato, H., Koga, Y. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol Immunother 57, 1007-1016 (2008).
30. Nagasawa, H., Sasaki, H., Uto, Y., Kubo, S., Hori, H. Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein. Anticancer Res 24, 3361-3366 (2004).
31. Kanda, S., Mochizuki, Y., Miyata, Y., Kanetake, H., Yamamoto, N. Effects of vitamin D(3)-binding protein-derivedmacrophage activating factor (GcMAF) on angiogenesis. J Natl Cancer Inst 94, 1311-1319 (2002).
32. Koga, Y., Naraparaju, V. R., Yamamoto, N. Antitumor effect of vitamin Dbinding protein-derived macrophage activating factor on Ehrlich ascites tumorbearing mice. Proc Soc Exp Biol Med 220, 20-26 (1999).
33. Nonaka, K. et al. Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice. J Surg Res 172, 116-122 (2012).
34. Speeckaert, M., Huang, G., Delanghe, J. R., Taes, Y. E. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 372, 33-42 (2006).
35. Yamamoto, N., Homma, S. Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88, 8539-8543 (1991).
36. Sonderman, J. S., Munro, H. M., Blot, W. J., Signorello, L. B. Reproducibility of serum 25-hydroxyvitamin d and vitamin D-binding protein levels over time in a prospective cohort study of black and white adults. Am J Epidemiol 176, 615-621 (2012).